Safinamide
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Safinamide: From Parkinson’s Disease to Rasmussen Subacute Encephalitis
One-Sentence Summary
Safinamide (Xadago) was originally authorized as add-on therapy to levodopa in adults with mid- to late-stage fluctuating Parkinson’s disease. The TxGNN model predicts it may be useful for Rasmussen subacute encephalitis, but this is a computational prediction only, with 0 clinical trials and 0 publications currently supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Add-on therapy to a stable dose of levodopa (alone or with other Parkinson’s medicines) in adults with idiopathic Parkinson’s disease who have mid- to late-stage fluctuations |
| Predicted New Indication | Rasmussen subacute encephalitis |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L5 |
| EU Market Status | Cancelled only (no currently valid authorization) |
| Number of Authorizations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Safinamide is generally known as a reversible MAO-B inhibitor, and its efficacy in Parkinson’s disease has been established through its marketing authorization. Any link to Rasmussen encephalitis rests on hypothesis, not on data.
One possible link is that safinamide also blocks voltage-gated sodium channels and reduces glutamate release. In theory, this could be relevant to the seizure activity and neuroinflammation-driven neuronal injury seen in Rasmussen encephalitis. This reasoning is unverified and cannot be cross-checked against a source mechanism record.
Rasmussen encephalitis is mainly an immune-mediated, progressive brain disease. Nothing in the data indicates that safinamide acts on the underlying immune process, so any benefit would at most be symptomatic.
Two other predictions were also generated, both with L5 evidence and a Hold recommendation:
- Myelitis (score 99.46%): A possible neuroprotective or anti-excitotoxic effect has been proposed. Myelitis covers infectious, autoimmune, and post-infectious causes, and nothing suggests safinamide addresses these.
- PLA2G6-associated neurodegeneration (score 99.22%): Safinamide might ease parkinsonian features, but it would not be expected to correct the underlying lipid-metabolism defect.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| EMEA/H/C/002396 | Xadago | Not specified | Xadago is indicated for the treatment of adult patients with idiopathic Parkinson’s disease (PD) as add-on therapy to a stable dose of Levodopa (L-dopa) alone or in… |
The only authorization on record has a cancelled status.
Safety Considerations
- Drug Interactions: The interaction screening returned 110 interacting drugs in total. Among the entries compiled for this report, the one rated Major is:
- Bupropion (Major)
Most of the other listed entries are rated Moderate, including:
- Antidiabetic agents (insulins, glimepiride, chlorpropamide, acetohexamide, nateglinide, repaglinide, empagliflozin)
- Sympathomimetic or stimulant-type agents (isometheptene, diethylpropion, phentermine)
- Metoclopramide
- Rosuvastatin
Please refer to the SmPC for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a graph-based model score, with no registered clinical trials and no published literature. The mechanistic link is hypothetical, and key mechanism and label safety data are missing.
To proceed, the following is needed:
- Mechanism of action data from DrugBank to test the proposed link
- The SmPC warnings and contraindications from the EMA website for safety screening
- A systematic literature and trial search for safinamide in Rasmussen encephalitis, including preclinical or case-level evidence
- Clarification of the current EU authorization status, since the only license is cancelled
- A review of the Major interaction (bupropion) and the Moderate interactions relevant to the target population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.